For the Inventor, By the Inventor

Enter assignee name

Richmond, VA, United States of America

Celtrix Pharmaceuticals, Inc.

USPTO Granted Patents = 45

Forward Citations = 1,218

Loading Chart...

Loading Chart...

41 inventors (with patents filed for the assignee):

Desmond D Mascarenhas (15 out of 31 patents)

Yasushi Ogawa (7 out of 12 patents)

Andreas Sommer (6 out of 8 patents)

4. David K Schmidt (5 out of 5 patents)

5. Pamela S Olson (5 out of 6 patents)

6. Joseph A Carlino (5 out of 6 patents)

7. Yang Zhang (4 out of 8 patents)

8. David R Olsen (4 out of 10 patents)

9. James R Dasch (4 out of 7 patents)

10. Rosa Armstrong (4 out of 15 patents)

11. Carol Talkington-Verser (4 out of 4 patents)

12. Christopher A Maack (4 out of 4 patents)

13. Emerald Martin Spencer (4 out of 4 patents)

14. Andrea Y Thompson (3 out of 6 patents)

15. Doran R Pace, Iii (3 out of 5 patents)

Core Competencies:

IGF Therapy

Monoclonal Antibodies

Drug Response Prediction

Ophthalmic Disorders

Bone Growth Factors

Chronic Stress Disorders

Metabolic Disorders

Recombinant Proteins

Inflammatory Cytokines

Hematopoietic Progenitor Cells

Insulin-like Growth Factor

Sex Hormone Steroids

45 patents: Sort by Forward Citations

1. 7288516 - Null IGF for the treatment of cancer (2007-10-30),

2. 6518238 - Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3 (2003-02-11),

3. 6514937 - Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3 (2003-02-04),

4. 6436897 - Pharmaceutical formulations for IGF/IGFBP (2002-08-20),

5. 6417330 - Insulin-like growth factor binding protein variants (2002-07-09),

6. 6124259 - Method for treating ophthalmic disorders with IGFBP (2000-09-26),

7. 6087090 - Methods for predicting drug response (2000-07-11),

8. 6040292 - Methods for treating diabetes (2000-03-21),

9. 6025368 - Method for treating the symptoms of chronic stress-related disorders (2000-02-15),

10. 6025332 - Method for treating low circulating levels of sex hormone steroids (2000-02-15),

11. 6017885 - IGF/IGFBP complex for promoting bone formation and for regulating bone (2000-01-25),

12. 6015786 - Method for increasing sex steroid levels using IGF or IGF/IGFBP-3 (2000-01-18),

13. 5948757 - High dose IGF-1 therapy (1999-09-07),

14. 5914390 - Methods for increasing yields of recombinant proteins (1999-06-22),

15. 5914254 - Expression of fusion polypeptides transported out of the cytoplasm (1999-06-22),

Company Overview

Celtrix Pharmaceuticals, Inc., based in Richmond, VA, specializes in the development of innovative therapeutic solutions targeting a range of medical conditions. The company focuses on advanced research in insulin-like growth factors and their binding protein variants, with applications in ophthalmic disorders and chronic stress-related conditions. Additionally, Celtrix is engaged in the exploration of recombinant proteins and their role in bone formation and hematopoietic progenitor cell development, contributing to the advancement of regenerative medicine.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

45 Patents

#17 in Richmond, VA

#130 in Virginia

#7,781 in US

#15,436 in the World

Richmond, VA, United States of America

Celtrix Pharmaceuticals, Inc.

Forward Citations = 1,218

41 inventors:

Desmond D Mascarenhas (15 out of 31 patents)

Yasushi Ogawa (7 out of 12 patents)

Andreas Sommer (6 out of 8 patents)

4. David K Schmidt (5 out of 5 patents)

5. Pamela S Olson (5 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Celtrix Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/celtrix-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…